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prescription, and information identifying both the patient and 
the prescribing optometrist or physician; and prohibits the 
filling of expired prescriptions except when the patient's spec­
tacles are damaged, broken, or lost. Under section 2559.6, it 
is unprofessional conduct to dispense spectacle lenses on or 
after January 1, 1999 for prescriptions that fail to meet the 
requirements of section 2541. 1. This bill was signed by the 
Governor on March 16 (Chapter 8, Statutes of 1998). 
AB 2721 (Miller), as amended August 10, establishes a 
four-year term of office, expiring on June 1, for members of 
the Board of Optometry. This bill also provides that any Board 
licensee who engages in, or aids and abets, prostitution-re­
lated offenses in the workplace is guilty of unprofessional 
conduct and subject to disciplinary action and fines up to 
$5,000. This bill was approved by the Governor on Septem­
ber 29 (Chapter 97 1 ,  Statutes of 1998). 
Recent Meetings 
At its November 14 meeting, the Board reelected Steven 
S. Grant, OD, as President and Gerald J. Easton, OD, as Vice 
President. Dr. John Anthony was elected Secretary, replacing 
Patricia L. Gee, EdD, in this position. Reappointed Board mem­
bers Dr. Sheilah Titus and Dr. Patricia Gee were also sworn in. 
Also at the November meeting, Dr. Grant reported on 
the progress of the 1998 occupational analysis study. An oc­
cupational analysis is designed to capture information with 
respect to the major tasks optometrists perform in their pro­
fessional work. [ 14: I CRLR 71 J Information on the knowl­
edge, skills, and abilities required of licensed optometrists in 
order to perform these tasks competently will be collected 
and used to evaluate the Board's current licensing examina­
tion for appropriateness of test parameters and criteria. Of 
2,000 surveys mailed to selected optometrists in September 
1998, 578 have been returned and submitted to R & D Data 
Corporation for tabulation and interpretation. DCA's Office 
Board of Pharmacy 
of Examination Resources is satisfied with both the numbers 
and demographic distribution of the surveys returned. The 
final report should be completed by early 1999. The results 
will not be ready by the next scheduled licensure exam (Janu­
ary 11, 1999 in Sacramento) but will be reflected in ques­
tions on the June 29, 1 999 examination. 
SB 668 (Polanco) (Chapter 13, Statutes of 1996) autho­
rizes the Board to certify optometrists who are qualified to 
use specific classes of therapeutic pharmaceutical agents 
(TPA) for a limited number of eye conditions, upon comple­
tion of specified education, training, and examination. Sec­
tion 1568 of the CCR, adopted by the Board in 1997 to imple­
ment SB 668, requires that applicants for TPA certification 
complete a Board-approved, 80-hour didactic course and 
specifies the University of California at Berkeley (UCB) and 
the University of Southern California (USC) as institutions 
where such a course will be offered. The Board has been work­
ing with UCB and USC to develop the TPA course. 
In November, the Board voted to approve a proposed 
TPA course which will be offered by UCB. The course will 
combine 60--65 hours of Internet and distance learning with 
15-20 hours of onsite, hands-on training at Berkeley. The 
course is being subsidized by Vision Service Plan (VSP), a 
national managed care provider of vision services, in a joint 
effort with UCB to reduce the financial hardships and acces­
sibility problems that have made it difficult for optometrists 
to obtain TPA certification. Terry Dougherty of VSP com­
mented that such a course will help VSP reach its goal of 
requiring that all VSP providers are TPA-certified. 
Future Meetings 
• March 1 4- 1 5, 1 999 in Fullerton. 
• May 1 6- 1 7, 1 999 in San Jose. 
• August 20-2 1 ,  1 999 in Sacramento. 
• November 1 4- 1 5, 1 999 in San Diego. 
Executive Officer: Patricia Harris ♦ (916) 445-5014 ♦ Internet: www.dca.ca.gov/pharmacy/ 
P
ursuant to Business and Professions Code section 4000 
et seq., the Board of Pharmacy grants licenses and per­
mits to pharmacists, pharmacy interns, pharmacy tech­
nicians, pharmacies, pharmacy corporations, nonresident 
pharmacies, wholesale drug facilities, medical device retail­
ers, veterinary food-animal drug retailers, out-of-state dis­
tributors, clinics, and hypodermic needle and syringe distribu­
tors. It regulates all sales of dangerous drugs, controlled sub­
stances, and poisons. The Board is authorized to adopt regu­
lations, which are codified in Division 17, Title 16 of the 
California Code of Regulations (CCR). 
To enforce the Pharmacy Law and its regulations, the Board 
employs full-time inspectors who investigate complaints re­
ceived by the Board. Investigations may be conducted openly 
or covertly as the situation demands. The Board conducts fact­
finding and disciplinary hearings, and is authorized by law to 
suspend or revoke licenses or per­
mits for a variety of reasons, includ­
ing professional misconduct and any 
misconduct substantially related to the practice of pharmacy. 
The Board of Pharmacy is a consumer protection agency 
located within the Department of Consumer Affairs (DCA). 
The Board, which meets five times per year, consists of eleven 
members, four of whom are nonlicensees. The remaining mem­
bers are pharmacists, five of whom must be active practitio­
ners. All Board members are appointed for four-year terms. 
Major Projects 
Data Collection Portion of CURES 
Pilot Project Commences 
For many years, the Board of Pharmacy has been involved 
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in a multi-agency project to automate the current paper-based 
"triplicate system" used when a physician or other authorized 
prescriber prescribes, and a pharmacist dispenses, Schedule 
II controlled substances. [ 15:4 CRLR 116; 15:2&3 CRLR 89; 
15: 1 CRLR 86 J Under the triplicate system, prescribers must 
prescribe Schedule II narcotics on 
a state-issued triplicate form. The - - - - -- - - - ·
· 
24; the Office of Administrative Law (OAL) approved the 
regulation on August 27. Section 1715.5 requires a dispens­
ing pharmacy to provide specified information on the patient, 
prescriber, and pharmacy for each prescription of a Schedule 
II controlled substance; specifies the format in which the in-
formation is to be provided; des­
prescriber retains one copy and 
gives the remaining two copies to 
the patient. To have the prescrip­
tion filled, the patient takes the re­
maining two parts of the form to 
a pharmacy. The pharmacy en­
dorses the prescription, retains a 
duplicate, and checks the form for 
compliance with Health and 
For m any years, the Board of Pharmacy 
has been involved in a multi-agency project 
to automate the current paper-based 
"triplicate system" used when a physician 
or other authorized prescriber prescribes, 
and a pharmacist dispenses, Schedule II 
controlled substances. 
ignates the Board of Pharmacy to 
select the location for submission 
of the information; establishes the 
timeframe for submitting infor­
mation; provides an alternate 
method of submission and thresh­
old reporting requirements for 
pharmacies without electronic re-
Safety Code section 11206. Section 11164 of the Health and 
Safety Code requires the pharmacy to transmit the original of 
the triplicate form to the Department of Justice's Triplicate 
Prescription Program at the end of the month in which the 
prescription was filled. 
The purpose of the triplicate system is to monitor closely 
the prescribing and dispensing of Schedule II controlled sub­
stances to control effectively the abuse and diversion of these 
narcotics while allowing patient access to appropriate medi­
cations. Prescription drug diversion is the illicit distribution, 
prescribing, dispensing, or use of controlled substances that 
are manufactured and intended for legitimate purposes. Drug 
diversion can occur at many points in the drug distribution 
chain, beginning with the manufacturer and ending with the 
patient or consumer. Much prescription drug diversion oc­
curs at the prescribing, dispensing, or patient level, which is 
predominantly the focus of the triplicate system. However, 
prescribers and dispensers complain that the paper-intensive 
triplicate system is burdensome in light of modern electronic 
recordkeeping methods. 
AB 3042 (Takasugi) (Chapter 738, Statutes of 1996) 
added section 11165 to the Health and Safety Code, which 
requires the Board of Pharmacy and the Department of Jus­
tice to establish the Controlled Substance Utilization Review 
and Evaluation System (CURES) to electronically monitor 
the prescribing and dispensing of Schedule II controlled sub­
stances by all practitioners authorized to prescribe or dispense 
them, "contingent upon the availability of adequate funds." 
In the meantime, AB 3042 requires that CURES be imple­
mented as a three-year pilot project commencing on July 1, 
1997, to be administered concurrently with the existing trip­
licate system, to examine the comparative efficiencies be­
tween the two systems. Thus, the statute requires the Depart­
ment of Justice and Board of Pharmacy to engage in a major 
data collection process to determine the relative efficiencies 
of the existing triplicate system and the electronic mainte­
nance of Schedule II narcotics data. 
To facilitate the collection of the required data, the Board 
adopted section 1715.5, Title 16 of the CCR, on April 10, 
1998 as an emergency regulation. Thereafter, it published 
notice of its intent to permanently adopt the section on April 
porting capability; specifies the 
reporting requirements for par­
tially filled or dispensed prescriptions; sets the compliance 
date for submission of information; and provides for a one­
time $75 reduction in the next license renewal fee for phar­
macies that comply with section 1715.5 by September 8, 1998. 
The Board has contracted with Atlantic Associates, Inc. 
in Manchester, New Hampshire to collect all the informa­
tion, and has sent several notices (with a CURES handbook) 
to all California pharmacies about the new reporting require­
ments. The Board warned pharmacies that the CURES project 
is operating concurrently with the existing triplicate prescrip­
tion program; thus, pharmacies are still required to mail origi­
nal triplicate prescription forms to the Department of Justice 
at the end of each month. 
The Board and the Department must submit a progress 
report on the data collection project to the legislature by J anu­
ary 1, 1999. When the pilot project is completed in June 2000, 
the legislature will determine the need for continuation of the 
current triplicate program. 
Licensing Limited Liability Companies 
At its October meeting, the Board's Licensing Commit­
tee discussed an emerging legal issue concerning the licen­
sure of a limited liability company (LLC) as a pharmacy. An 
LLC is a form of business enterprise established in 1994 by 
the Beverly-Killea Limited Liability Company Act, Corpo­
rations Code section 11000 etseq. [ 14:4 CRLR 120JThe LLC 
structure offers business owners the limited liability of a cor­
poration and the pass-through tax advantages of a partner­
ship. An uncodified provision of the Beverly- KilleaAct pro­
hibits an LLC from rendering "professional services." Ac­
cording to a March 1998 legal opinion by DCA attorney Chris­
topher Grossgart, it is generally accepted that the uncodified 
language prevents DCA and its constituent licensing agen­
cies from issuing "professional" licenses to an LLC; for ex­
ample, an LLC is precluded from holding a license to prac­
tice as a pharmacist, a dentist, or a physician. 
A more controversial question has been whether the 
uncodified language also prevents a DCA agency from issuing 
a permit to an LLC to operate a business in which professional 
services are rendered, and in fact dozens of LLCs have sub­
mitted applications to the Board for pharmacy, medical device 
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retailer, and wholesaler licenses. Based on DCA advice, the 
Board has interpreted the uncodified language narrowly and 
has denied the issuance of these licenses to LLCs. Applicants 
have countered that these pennits are merely "business" licenses 
and, as such, are not encompassed within the prohibition against 
an LLC rendering "professional" services. Whether a distinc­
tion can be made between "professional" and "business" li­
censes has been the subject of great dispute. The Department 
of Health Services (OHS) for example, has rejected DCA's 
narrow construction of the uncodified language. 
In a subsequent October 8 memo, Grossgart recom­
mended that the Board consider sponsoring legislation add­
ing section 4208 to the Business and Professions Code, which 
would authorize it to issue "site" permits to an LLC to oper­
ate as a pharmacy, medical device retailer, wholesaler, or vet­
erinary medical drug retailer. As the law currently authorizes 
the Board to issue "site" permits to corporations which have 
the same liability shield as an LLC, this proposed legisla­
tion-in Grossgart's view-would not adversely affect con­
sumer protection. 
At the full Board's October 28 meeting, member Darlene 
Fujimoto expressed concern that licensure ofLLCs might be 
unrelated to the Board's overall strategic plan and asked how 
such licensure would benefit the practice of pharmacy. Deputy 
Attorney General Bill Marcus re-
(e.g., anything of value, including supplies and drugs) in or­
der to induce business reimbursed by a federally funded pro­
gram such as Medicare, Medicaid, or CHAMPUS. Califor­
nia also has an anti-kickback statute at Welfare and Institu­
tions Code section 14107.2(a). In its advisory opinion, OIG 
described a particular case in which a hospital provided sup­
plies without charge to municipal ambulance companies. 
Because the ambulance company could influence a patient's 
choice of hospital, and because of the risk that an ambulance 
company would use its influence to direct a patient to a hos­
pital that provides the ambulance company with free goods, 
OIG concluded that the arrangement would likely constitute 
prohibited remuneration under the federal anti-kickback stat­
ute. In OIG's view, state law giving patients the right to de­
termine their destination is insufficient to deter abuse where 
the hospital provides remuneration, including the provision 
of free goods, to the ambulance service. 
Adopting the position of CHA, many hospitals have dis­
continued the practice of restocking ambulances. This is not a 
problem for general supplies, but concerns have arisen about 
the issue of restocking of controlled substances. Some ambu­
lances are purchasing, storing, and restocking medications and 
supplies. For controlled substances, they are using the license 
and DEA certificate of their contracted medical director. Ac-
cording to Pharmacy Board Execu­
sponded that allowing licensure to 
LLCs would decrease the Board's 
exposure to litigation. He reiter­
ated that a considerable number 
of LLCs have applied for licen­
sure to establish pharmacies and 
The Board has recently been asked to tadde 
a thorny problem regarding the restocking 
of ambulance supplies (including drugs) by 
hospitals. 
tive Officer Patricia Harris, the 
Pharmacy Law does not specifi­
cally authorize clinics or hospital 
medical directors (or other physi­
cians) to supply emergency ve­
hicles with dangerous drugs, dan­
are likely to challenge the Board when their applications are 
denied. Because some LLCs were granted licenses before 
DCA's position on LLCs was clear, some applicants have sug­
gested that the Board has acted arbitrarily. 
At its October 28 meeting, the Board voted unanimously 
to refer the issue whether to seek the addition of Business and 
Professions Code section 4208 to its Legislation and Regula­
tion Committee for study and recommendation to the Board. 
Restocking of Ambulances with 
Supplies and Medications 
The Board has recently been asked to tackle a thorny 
problem regarding the restocking of ambulance supplies (in­
cluding drugs) by hospitals. The Health Care Financing 
Administration's Office of the Inspector General (OIG) has 
released an advisory opinion which concludes that a hospital's 
restocking of ambulance supplies likely violates federal anti­
kickback law and raises several other legal problems, includ­
ing antitrust, tax, pharmacy, and contract law issues, and pos­
sible violation of the federal False Claims Act. Relying on 
OIG's opinion, the California Healthcare Association (CHA) 
has adopted a policy of discouraging the common practice of 
hospitals restocking ambulance supplies (including drugs). 
Federal anti-kickback law, 42 U.S.C. section 1320a-
7b(b ), sets forth penalties for individuals or entities that know­
ingly and willfully offer, pay, solicit, or receive remuneration 
gerous devices, or controlled substances. Any specific author­
ity must be found elsewhere, such as federal or state law and 
regulations governing emergency vehicles. 
On October 28, the Board voted unanimously to form a 
task force with representatives from the California Society of 
Health Systems Pharmacists, the Department of Health Ser­
vices, and possibly the Office of Emergency Services to draft 
legislation that would authorize the storage, dispensing, and 
purchasing of dangerous drugs and devices for use by emer­
gency personnel. 
Implementation of the FDA Modernization 
Act of 1 997 
On November 9, 1997, Congress passed the Food and 
Drug Administration Modernization Act of 1997. The law was 
signed by President Clinton on November 21 ,  1997 and be­
came effective on November 21 ,  1998. The FDA Moderniza­
tion Act of 1997 requires FDA and the fifty states to enter 
into a memorandum of understanding (MOU) regarding the 
compounding of drugs. Compounding is the process by which 
a pharmacist combines, mixes, or alters ingredients to spe­
cialize a medication for a patient, at the direction of a physi­
cian. Section 503A of the Act recognizes compounding as an 
element of the practice of pharmacy that is to be regulated by 
the states, and distinguishes it from "manufacturing" which 
falls within the jurisdiction of the FDA. The purpose of the 
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section is "to ensure continued availability of compounded 
drug products as a component of individualized therapy, while 
limiting the scope of compounding so as to prevent manufac­
turing under the guise of compounding." The purpose of the 
MOU is to address the interstate distribution of "inordinate 
amounts" of compounded drug products and a state's investi­
gation of complaints regarding this distribution. 
The law instructs the FDA and the National Association 
of Boards of Pharmacy (NABP) to develop a standard MOU 
for state boards. The goal of the MOU is to obtain state agree­
ment on two issues: (1) protocols for the appropriate investi­
gation of complaints relating to compounded drug products 
shipped out-of-state; and (2) establishment of appropriate 
restrictions on the amount of compounded drugs shipped in 
interstate commerce, including "safe harbors" for pharma­
cists who distribute compounded products in interstate com­
merce. Pharmacies located in a state that does not sign a MOU 
by the law's effective date (November 21) will be subject to 
FDA's "safe harbor" provision, whereby compounded prod­
ucts may not exceed 5% of the total prescription orders dis­
pensed or distributed by that pharmacy. The MOU's "safe 
harbor" language is intended to address circumstances in 
which interstate distribution of compounded medications can 
exceed 5% of the total quantity of dispensed medication. 
At its October 28 meeting, the Board decided it would 
take no action at the time; the Board directed the Licensing 
Committee to monitor the progress of the MOU being devel­
oped by the FDA and NABP. 
Recycling of Nursing Home Drugs 
The American Medical Association recently adopted a 
policy reflecting recommendations made by its Council on 
Scientific Affairs in a written report entitled Recycling of Nurs­
ing Home Drugs. The report makes recommendations on ways 
to reduce medication waste in long-term care facilities 
(LTCFs ). The report defines "medication waste" as any medi­
cation that has been dispensed and paid for but not consumed 
by a particular LTCF patient. Based on limited studies, the 
report stated that the cost associated with unused medication 
in LTCFs is 4-10% of the total costs of medications dispensed. 
More than 90% of the wasted medication is due to discon­
tinuation or change in medication or the death, transfer, or 
hospitalization of the resident. 
Based on the report, the AMA has adopted a policy con­
sistent with the American Society of Consultant Pharmacists 
(ASCP) to support the return and reuse of medications to the 
dispensing pharmacy to reduce waste associated with unused 
medications in LTCFs and to offer substantial savings to the 
health care system. AMA and ASCP recommend that medi­
cations be returned and reused only if (1) they are not con­
trolled substances, (2) they are dispensed in tamper-evident 
packaging and returned with packing intact, (3) in the profes­
sional judgment of the pharmacist, the medications meet all 
federal and state standards for product integrity, (4) policies 
and procedures are followed for the appropriate storage and 
handling of medications at the LTCF and for the transfer, re­
ceipt, and security of medications returned to the dispensing 
pharmacy, (5) a system is in place to track restocking and 
reuse to allow medications to be recalled if required, and (6) 
a mechanism (reasonable for both the payer and the dispens­
ing LTCF pharmacy) is in place for billing only the number 
of doses used or crediting the number of doses returned, re­
gardless of payer source. 
On October 28, the Board unanimously voted to adopt 
the Licensing Committee's recommendation that the Board 
participate as a member of a task force with interested parties 
to address the issue of recycling nursing home drugs. 
Acceptable Remedial Pharmacy Coursework 
SB 1349 (Committee on Business and Professions) (Chap­
ter 549, Statutes of 1997) added section 4200. 1 to the Business 
and Professions Code; effective July 1, 1998, this provision 
requires candidates who have failed the Board's licensure ex­
amination after four attempts to complete 16 semester units or 
the equivalent of pharmacy coursework approved by the Board 
as a condition of eligibility for reexamination. 
In April 1998, the Board published notice of its intent to 
adopt section 1725, Title 16 of the CCR, to specify the crite­
ria for acceptable remedial pharmacy coursework. Under sec­
tion 1725, coursework that meets the requirements of section 
4200. 1 of the Business and Professions Code is any phar­
macy coursework offered by a pharmacy school approved by 
the American Council on Pharmaceutical Education or rec­
ognized by the Board. A final examination must be part of 
the course of study. When a candidate applies for reexamina­
tion after four failed attempts, he/she must furnish evidence 
of successful completion of at least 16 semester units or the 
equivalent of remedial pharmacy coursework; evidence of 
successful completion must be posted on a transcript from 
the pharmacy school sent directly to the Board. Following a 
45-day public comment period, the Board adopted section 
1725; OAL approved the regulation on October 5, and it be­
came effective on November 4. 
Practical Training for Pharmacy Technician Trainees 
Business and Professions Code section 4115 establishes 
the pharmacy technician category, and directs the Board to adopt 
regulations specifying that tasks which may be performed by a 
pharmacy technician under the direct supervision of a licensed 
pharmacist; section 1793.2, Title 16 of the CCR, specifies those 
tasks. Business and Professions Code section 4202 requires 
the Board to adopt regulations setting forth the qualifications 
for registration as a pharmacy technician, and the required con­
tents of acceptable pharmacy technician training courses. Sec­
tion 1793.4, Title 16 of the CCR, sets forth the qualifications 
for pharmacy technician registration; under section 1793.4(d), 
one method of qualification is to work for at least one year 
performing the tasks specified in section 1793.2 while employed 
or utilized as a pharmacy technician, assisting in the prepara­
tion of prescriptions for an inpatient of a hospital or for an 
inmate of a correctional facility. Section 1793.6, Title 16 of the 
CCR, specifies a three different methods of qualifying for phar­
macy technician registration, and the types of knowledge which 
an acceptable training program should impart to a registration 
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candidate. One of the approved types of training programs 
places a pharmacy technician trainee in a pharmacy to perform 
the functions of a pharmacy technician under the direct super­
vision and control of a licensed pharmacist. 
Effective July 1 ,  1997, SB 1553 (Kelley) (Chapter 798, 
Statutes of 1996) removed an exemption from the pharmacy 
technician registration requirement for persons employed or 
utilized as a pharmacy technician to assist in the filling of pre­
scriptions for an inpatient of a hospital or for an inmate of a 
correctional facility. This amendment created "catch-22" prob­
lems for the Board and for individuals then enrolled in phar­
macy technician training programs, because it could be inter­
preted to preclude persons serving an extemship in a pharmacy, 
and attempting to qualify for pharmacy technician registration 
under section l 793.4(d), from obtaining the required training. 
In early 1998, the Board drafted legislation to fix the 
problem created by SB 1553; the language was ultimately 
amended into SB 2239 (Committee on Business and Profes­
sions), which was passed by the legislature and becomes ef­
fective on January 1 ,  1999 (see LEGISLATION). In the mean­
time, the Board amended section 1793.6, Title 16 of the CCR, 
on an emergency basis in August 1 997, and then readopted 
the emergency amendments on several occasions throughout 
1998 .  Under the amendments, a current enrollee of a 
pharmacy technician training course that meets the require­
ments of section 1793.6 may obtain all or part of his/her prac­
tical instruction as an enrollee of that course in a pharmacy; 
such an enrollee must wear a badge that clearly identifies him/ 
her as a "pharmacy technician trainee." The amendments fur­
ther state that the tasks performed by the trainee must be lim­
ited to the ta�ks described in section 1793.2, and require that 
the tasks be performed in compliance with state and federal 
laws and with verification and documentation by a licensed 
pharmacist as required by subsections l 793.7(a) and (b). 
SB 2239 has now fixed this problem by adding section 
41 15.5 to the Business and Professions Code, which clarifies 
that, notwithstanding any other provision of law, a pharmacy 
technician student may be placed in a pharmacy as a phar­
macy technician trainee to complete an externship for the 
purpose of obtaining practical training that is required by the 
Board as a condition of becoming registered as a pharmacy 
technician. The new statute also sets forth standards for the 
supervision of pharmacy technician trainees serving in 
externships in pharmacies. 
Board PrOf)oses to Reduce License Renewal Fees 
Sections 17  49 . 1  and 1793.5, Title 16 of the CCR, set forth 
various fees and penalties charged by the Board for licenses, 
permits, registrations, and other services. Business and Pro­
fessions Code section 4400(s) directs the Board to maintain a 
reserve fund equal to approximately one year's expenditures. 
In the early 1990s, to help offset a large budget deficit in 
the state's general fund, the state 's Budget Act permitted the 
director of the Department of Finance to remove any surplus 
exceeding three months of operating expenses from any spe­
cial fund agency. [ 12:4 CRLR 1 J In the case of the Board of 
Pharmacy, $5.4 million was transferred from the Board's 
reserve fund to the general fund. This transfer made it difficult 
for the Board to meet operational expenses with respect to its 
enforcement and consumer awareness programs. To help meet 
its expenses, the Board sought a fee increase, which was granted 
and became effective on July 1 ,  1995. [ 15:2&3 CRLR 90] 
On behalf of the licensees of a number of occupational 
agencies whose reserve funds were raided by the state, Los 
Angeles attorney Richard Fine sued the state to compel reim­
bursement of the removed funds. [ 15:4 CRLR 39-40] The 
state recently settled the lead case, Malibu Video Systems, et 
al. v. Kathleen Brown, et al. , No. BC082830 (Los Angeles 
County Superior Court), and agreed to refund the monies to 
the agencies over a multi-year period. In fiscal year 1998-
99, the Board of Pharmacy was reimbursed $3,798,197 of 
the $5.4 million transferred to the general fund in fiscal year 
1991-92. The Board anticipates the return of an additional 
$ 1 , 1 38,990 during fiscal year 1999-2000. Based upon pro­
jected revenues and expenditures, the Board will end fiscal 
year 1999-2000 with a reserve of 19.6 months' worth of op­
erational expenditures; it will have 1 8.9 months by fiscal year 
2000-2001 ,  and 17.9 months by fiscal year 2001-2002. 
In light of this recovery, the Board published notice on 
November 27 of its intent to reduce its pharmacist and phar­
macy renewal fees in order to slow the accrual of funds and 
achieve a fund level consistent with approximately one year's 
operating expenses. The Board has determined that the pro­
posed regulatory action would reduce its reserve fund to a 
level of 16.6 months by fiscal year 1999-2000, 1 3.0 months 
by fiscal year 2000-2001 ,  and 9.2 months by 2001-2002. The 
fund level achieved by 2001-2002 would be consistent with 
the provisions of Business and Professions Code section 
4400(s), and would be considered prudent by DCA and the 
Department of Finance. 
Under the Board's proposed amendments, its pharma­
cist biennial renewal fee would be $ 1 15, and its annual phar­
macy renewal fee would be $175, effective July 1 ,  1999. At 
this writing, the Board does not plan to hold a public hearing 
on the proposed amendments, but is accepting written com­
ments until January 1 1 ,  1999. 
Legislation 
SB 2239 (Committee on Business and Professions), as 
amended August 24, enacts various technical changes affect­
ing licensing boards within DCA; several of the bill's provi­
sions affect the Board of Pharmacy. 
As noted above, SB 2239 adds section 41 15.5 to the Busi­
ness and Professions Code, concerning pharmacy technician 
trainee externships (see MAJOR PROJECTS). This provision 
expressly authorizes any pharmacy technician student (defined 
as a person enrolled in a pharmacy technician training pro­
gram operated by a California public postsecondary educa­
tion institution or by a private postsecondary vocational insti­
tution approved by the Bureau for Private Postsecondary and 
Vocational Education) to be placed in a pharmacy as a phar­
macy technician trainee to complete an externship for the pur­
pose of obtaining practical training that is required by the Board 
as a condition of becoming registered as a pharmacy techni-
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ciao . The new provision also states that a pharmacy techni­
cian trainee participating in such an externship may perform 
pharmacy technician duties only under the immediate and 
personal supervision and control of a pharmacist who is on 
the premises and has the trainee within his/her view at any 
time the trainee performs such duties. The pharmacist is di­
rectly responsible for the conduct of the trainee, and must verify 
any prescription prepared by the trainee by initialing the pre­
scription label before the medication is disbursed to a patient. 
No more than one pharmacy technician trainee per pharma­
cist may participate in an externship. An externship may last 
up to 120 hours; however, if the extemship involves a rotation 
between a community and hospital pharmacy for the purpose 
of training the student in distinct practice settings, it may last 
for 320 hours. At all times while on the job, the trainee must 
wear identification that indicates his/her student status. 
SB 2239 also amends section 4301 of the Business and 
Professions Code to restore cash compromise as unprofes­
sional conduct and grounds for disciplinary action. Last year's 
SB 1349 repealed this subsection since the Board's prosecu­
tors had not used it in years. However, as SB 1349 was near­
ing enrollment, a cash compromise case appeared. SB 2239 
restores section 4301(m) to define the cash compromise of a 
charge of violation of Chapter 13 (commencing with Section 
801) of Title 21 of the United States Code regulating controlled 
substances as unprofessional conduct; the record of the com­
promise is conclusive evidence of unprofessional conduct. 
SB 2239 adds section 4301.5 to the Business and Profes­
sions Code to provide that if a California-licensed pharma­
cist is also licensed in another state or jurisdiction, and that 
other state or jurisdiction suspends or revokes that license, 
the pharmacist's California license shall be suspended auto­
matically for the duration of the other state's suspension or 
revocation. The Board must notify the pharmacist regarding 
the status of his/her California license and of his/her right to 
have the issue of penalty heard under a new expedited proce­
dure established in this section. 
SB 2239 also amends section 4322 of the Business and 
Professions Code to impose substantially higher civil penal­
ties and fines on a person who attempts to secure or secures 
licensure for him/herself or another person by making false 
representations, or who fraudulently represents him/herself 
to be licensed. This offense is punishable as a misdemeanor; 
upon conviction, a fine of $5,000 (increased from $400) and 
imprisonment of 50 days could be imposed. 
The bill also amends Health and Safety Code section 
11166 to permit pharmacists to fill prescriptions for Sched­
ule II drugs within 14 days after the triplicate was written; 
existing law prohibits dispensing if the prescription is "ten­
dered" to the pharmacist seven days after it is issued. 
Finally, SB 2239 repeals and reenacts Health and Safety 
Code section 11167 to extend from 72 hours to seven days 
the period within which a prescriber's emergency oral order 
for a Schedule II drug must be followed by the triplicate pre­
scription. This bill was signed by the Governor on Septem­
ber 26 (Chapter 878, Statutes of 1998). 
SB 440 (Maddy). Under existing law, a pharmacist may 
perform certain procedures or functions as part of the care 
provided by a health care facility, a licensed clinic, or a pro­
vider under contract with a health plan, in accordance with 
policies, procedures, or protocols of that facility, licensed 
clinic, or health plan. As amended June 25, SB 440 permits a 
pharmacist to also perform procedures and functions as part 
of the care provided by a home health agency licensed by the 
state Department of Health Services . A pharmacist perform­
ing any of these procedures for a licensed home health agency 
must perform the procedures in accordance with a written, 
patient-specific protocol approved by the treating or super­
vising physician; any change, adjustment, or modification of 
an approved preexisting treatment or drug therapy must be 
provided in writing to the treating or supervising physician 
within 24 hours . This bill was signed by the Governor on 
August 21 (Chapter 347, Statutes of 1998). 
SB 625 (Rosenthal), as amended April 23, requires health 
plans that provide prescription drug benefits and maintain one 
or more drug formularies to provide to members of the pub­
lic, upon request, a copy of the current list of prescription 
drugs on the formulary by major therapeutic category; and to 
maintain an expeditious process by which prescribing pro­
viders may obtain authorization for a medically necessary 
nonformulary prescription drug. This bill was signed by the 
Governor on June 19 (Chapter 69, Statutes of 1998). 
AB 974 (Gallegos), as amended June 3, prohibits health 
plan contracts covering prescription drug benefits that are is­
sued, amended, or renewed on or after July 1, 1999 from lim­
iting or excluding coverage for a drug for an enrollee if the 
drug previously had been approved for coverage by the plan 
for a medical condition of the enrollee and the plan's pre­
scribing provider continues to prescribe the drug for the medi­
cal condition, provided that it is appropriately prescribed and 
is considered safe and effective for treatment. This bill does 
not preclude the prescribing provider from prescribing an­
other drug that is covered by the plan and is medically appro­
priate, nor does it prohibit generic drug substitutions pursu­
ant to specified existing law. AB 97 4 also requires every health 
plan that covers prescription drug benefits to comply with 
certain notice requirements with respect to whether the plan 
uses a formulary and to provide certain information about 
drugs on the formulary to the public, upon request. Under 
AB 974, plans that use a formulary must provide an enrollee 
or member of the public, upon request, with a list of all of the 
drugs contained in the plan's formulary, and provide infor­
mation, by telephone, about whether specific drugs are on 
the plan's formulary. This bill was signed by the Governor on 
June 19 (Chapter 68, Statutes of 1998). 
SB 1606 (Lewis), as amended August 24, provides that, 
commencing July 1, 1999, limitations imposed on the num­
ber or quantity of oral or suppository form drugs provided by 
a pharmacy to a skilled nursing or intermediate care facility 
shall not apply to an automated drug delivery system, when a 
pharmacist controls access to the drugs. [ 15:4 CRLR 117-
18] The bill also provides that, commencing July 1, 1999, 
access to an automated drug delivery system shall be limited 
to personnel authorized by law to administer drugs and who 
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have an access code to the system; sets forth requirements of prescription must also indicate that the prescriber has certi-
a health facility and pharmacy with regard to the installation, fled that the patient is terminally ill by the words " 1 1 159.2 
operation, and review of an automated drug delivery system; exemption." The bill further authorizes a pharmacist to fill 
and exempts an automated drug delivery system from certain such a prescription when there is a technical error in the cer-
Iabeling requirements. This bill was signed by the Governor tification, provided that he/she has personal knowledge of 
on September 22 (Chapter 778 , Statutes of 1998). the patient's terminal illness, and subsequently returns the 
AB 1889 (Knox), as amended August 25, would have prescription to the prescriber for correction within 72 hours. 
required the Board of Pharmacy to conduct a study of The bill defines "terminally ill" as a patient who, in the 
medication error rates and negative drug interaction, using reasonable medical judgment of the prescribing physician, 
$300,000 from the Board's Contingent Fund. The Governor has been determined to be suffering from an illness that is 
vetoed the bill on September 27. In his veto message, the incurable and irreversible; whose illness, in the reasonable 
Governor stated that the methodology of the study was medical judgment of the prescribing physician, will, if the 
wrongly conceived and that the study was potentially unnec- illness takes its normal course, bring about the death of the 
essary because current pending studies could provide the same patient within a period of one year; and whose treatment by 
information sought by the proposed study. the physician prescribing a Schedule II controlled substance 
AB 2687 (Gallegos), as amended August 28, authorizes is primarily for the control of pain , symptom management, 
a local health officer who determines that a person within or both, rather than for cure of the illness. 
his/her jurisdiction is unlawfully dispensing or furnishing dan- The Board opposed AB 2693 for several reasons. First, 
gerous drugs or devices to take action to stop such sales, in- the Board asserted that some patients would learn that the 
eluding receiving and investigating complaints from the pub- term " 1 1 1 59.2 exemption" means they have a terminal ill-
lic, other licensees, or health care facilities; issuing an order ness, which would undermine attempts to keep terminal di-
to the person to immediately cease and desist from the un- agnoses from patients. Second, the bill obligates the pharma-
lawful activity; and ordering the closure of the business op- cist to assure the patient is terminally ill to be exempt from 
erated, managed, or owned by that person. The bill also au- the triplicate prescription, requiring the pharmacist to con-
thorizes a local health officer to order the immediate closure tact the prescriber for verification. Third, the Board fears that 
of a business upon reasonable suspicion that the business poses the bill will facilitate drug diversion of Schedule II drugs by 
an immediate threat to public health, welfare, or safety. The creating another way to prescribe, dispense, and account for 
bill requires that any person whose ··· ·-· . ---- ··· _ - - ·  _ • __ . .. the dispensing of Schedule II 
business is closed as a result of local Effective January I ,  1999; section 171 5  drugs without compliance 
health officer action be given notice requires the pharmacist-in-charge of each I with the triplicate
 system. Fi-
and a hearing to show cause why the pharmacy to complete a self-assessment . 1 nally, the Board argued that 
closure is unwarranted. This bill ofthepharmacyts compliancewith federal i because the CURES report is 
makes it a misdemeanor for any unli- ; and state pharmacy laws. due by January 1 ,  1999, this 
censed person to knowingly dispense bill is premature in its piece-
or furnish a dangerous drug or dan- meal elimination of the tripli-
gerous device, or to knowingly own, manage, or operate a cate requirement for this category of prescription. However, 
business that dispenses or furnishes a dangerous drug or dan- this bill was signed by the Governor on September 23 (Chap-
gerous device, when that business is not licensed to dispense ter 789, Statutes of 1998). 
or furnish such products. Upon conviction, each violation is AB 2721 (Miller), as amended August 10, clarifies that 
punishable by imprisonment in a county jail not to exceed Pharmacy Board members serve a term of four years, expir-
one year, or by a fine not to exceed $5,000, or by both that ing on June 1 .  The bill also provides that any Board licensee 
fine and imprisonment. Upon a second or subsequent con- who engages in, or aids and abets, prostitution in the work-
viction, each violation is punishable by imprisonment in a place is guilty of unprofessional conduct and is subject to 
county jail or by fine. This bill was signed by the Governor disciplinary action against his/her license; the bill also pro-
on September 22 (Chapter 750 of the Statutes of 1998). vides for the imposition of a civil penalty in such cases. This 
AB 2693 (Migden), as amended August 18 ,  provides that bill was signed by the Governor on September 29 (Chapter 
a prescription for a Schedule II controlled substance for use 971 ,  Statutes of 1998). 
by a patient who has a terminal illness is exempt from the SB 2238 (Committee on Business and Professions), as 
triplicate requirement; however it must comply with require- amended August 26, requires the Board of Pharmacy to ini-
ments set forth in the bill. AB 2693 requires such a prescrip- tiate the rulemaking process on or before June 30, 1999, to 
tion to be signed and dated by the prescriber and to contain adopt regulations requiring its licentiates to provide notice to 
the name of the person for whom the controlled substance is clients and customers that they are licensed by the state of 
prescribed, the name and quantity of the controlled substance California. SB 2238 also requires the Board to submit to the 
prescribed and directions for use, the address of the person DCA Director, on or before December 3 1 ,  1999, its method 
for whom the controlled substance is prescribed, and specific for ensuring periodic evaluation of every licensing examina-
information about the prescriber such as telephone number tion that it administers. This bill was signed by the Governor 
and federal controlled substance registration number. The on September 28 (Chapter 879, Statutes of 1998). 
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Recent Meetings 
At its October meeting, Board staff gave a presentation to 
the Board on its new "self-assessment" program under section 
1715, Title 16 of the CCR. Effective January 1, 1999, section 
1715 requires the pharmacist-in-charge of each pharmacy to 
complete a self-assessment of the pharmacy's compliance with 
federal and state pharmacy laws. The assessment must be 
performed before March 31 of every odd-numbered year. The 
pharmacist-in-charge must also complete a self-assessment 
within 30 days whenever ( 1) a new pharmacy permit has been 
issued, or (2) there is a change in the pharmacist-in-charge. 
The primary purpose of the self-assessment is to pro­
mote compliance with the law through self-examination and 
education. The Board has developed two forms to guide a 
pharmacist's self-assessment: Form 171-29 is for community 
pharmacies, and Form 171-30 is for hospital inpatient phar­
macies. The forms require the pharmacist-in-charge to evalu­
ate the pharmacy's compliance with federal and state laws 
and regulations regarding facility condition and security, drug 
stock, posting of certificates and notices, pharmacist-in-charge 
obligations, intern pharmacist activities, pharmacy technician 
activities, general pharmacy practice, corresponding respon­
sibility for filling controlled substances prescriptions, pre­
scription requirements, prescription labeling and dispensing, 
refill authorization, prescription transfers, confidentiality of 
prescriptions, recordkeeping requirements for all dangerous 
drugs, recordkeeping requirements for controlled substances, 
automated dispensing devices, repackaging for use by the 
pharmacy, compounding unapproved drugs for future use or 
prescriber use, and electronic transmission of prescriptions. 
Each self-assessment must be kept on file in the pharmacy 
for three years after it is performed. 
Future Meetings 
• January 20-2 1 ,  1 999 in Orange County. 
• March 24-25, 1 999 in Sacramento. 
• May 1 2- 1 3, 1 999 in San Diego. 
• July 28-29, 1 999 in San Francisco. 
• October 20-2 1 ,  1 999 in Sacramento. 
Board of Podiatric Medicine 
Executive Officer: James H. Rathlesberger ♦ (916) 263-2647 ♦ Internet: www.dca.ca.gov/bpml 
The Board of Podiatric Medicine (BPM) regulates the practice of podiatry in California pursuant to Business and Professions Code section 2460 et seq. and Article 
12 of the Medical Practice Act (Business and Professions Code 
section 2220 et seq.). BPM's regulations appear in Division 
13.9, Title 16 of the California Code of Regulations (CCR) . 
The mission of the Board of Podiatric Medicine is to 
ensure the protection of consumers through proper use of the 
licensing and enforcement authorities delegated to it by the 
legislature. BPM is a consumer protection agency within the 
Department of Consumer Affairs (DCA) and its Medical 
Board of California (MBC) . 
The Board licenses doctors of podiatric medicine 
(DPMs), administers two licensing tests per year, approves 
colleges of podiatric medicine, and enforces professional stan­
dards by initiating investigations and taking disciplinary ac­
tion where appropriate. The Board consists of four licensed 
podiatrists and three public members. 
Major Projects 
8PM Undergoes the Sunset Review Process 
During the fall of 1997, the necessity and performance of 
BPM were reviewed by the Joint Legislative Sunset Review 
Committee (JLSRC) and DCA under the "sunset review" pro­
cess set forth in SB 2036 (McCorquodale) (Chapter 908, Stat­
utes of 1994). Under the sunset process, the legislature inserts 
an expiration date into the enabling act of each DCA regula­
tory board; prior to that date, the JLSRC must review the need 
for and performance of the board, and the legislature must pass 
a bill extending the life of the 
agency or it ceases to exist. [ 15:4 
CRLR 32] As required under the 
statute, BPM submitted a lengthy 
report describing its mission, func­
tions, and activities on October 1 ,  and answered questions from 
JLSRC members at a hearing on November 17, 1997. 
BPM's sunset report contained some interesting and 
somewhat controversial recommendations. First, BPM rec­
ommended that its composition be converted from a profes­
sional member majority to a public member majority. At the 
time, the Board was composed of four podiatrists and two 
public members. Although most non-health care occupational 
licensing boards (with the exception of the Board of Accoun­
tancy) are dominated by public members, only one Califor­
nia health care licensing board-the Board of Vocational 
Nurses and Psychiatric Technicians-consists of a public 
member majority, and it only recently achieved that status 
during its 1 996-97 sunset review process. BPM proposed to 
become the second, with a nine-member board consisting of 
five public members and four DPMs. 
BPM first voted to seek a public member majority in 
November 1995 . [15:4 CRLR 104] Throughout 1996 and 
1997, BPM held public hearings on its proposal to convert to 
a public member majority. Strenuously opposing the proposal 
at every hearing was the California Podiatric Medical Asso­
ciation (CPMA). At BPM's sunset hearing, CPMA testified 
that "the Board of Podiatric Medicine is fulfilling its public 
protection role in an exemplary fashion with its current pro­
fessional member majority." CPMA stated that it is unaware 
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